Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A2P4LJ5
Wed, 19.04.2023
PharmaSGP Holding SE
PharmaSGP plans dividend distribution of 49.2% after record year in 2022
Gräfelfing, 19 April 2023 – The German OTC pharmaceutical company, PharmaSGP Holding SE (WKN A2P4LJ), remains on track for highly profitable growth. The Munich-based company posted the best set of figures in its history in financial year 2022, generating revenue of € 85.8 [ … ]
Wed, 15.03.2023
PharmaSGP Holding SE
PharmaSGP confirms record revenue and record profitability for 2022 and publishes forecast for 2023
Gräfelfing, 15 March 2023 – Based on preliminary and unaudited figures German OTC pharmaceutical company PharmaSGP Holding SE has achieved a significant increase of 31.3% in revenue resulting in a new record of € 85.8 million in financial year [ … ]
Wed, 15.03.2023
PharmaSGP Holding SE
PharmaSGP confirms record revenue and record profitability for 2022 and publishes forecast for 2023
Gräfelfing, 15 March 2023 – Based on preliminary and unaudited figures German OTC pharmaceutical company PharmaSGP Holding SE has achieved a significant increase of 31.3% in revenue resulting in a new record of € 85.8 million in financial year [ … ]
Mon, 20.02.2023
PharmaSGP Holding SE
PharmaSGP achieves new record revenue of more than € 85.5 million for 2022 exceeding analysts’ expectations
Gräfelfing, 20 February 2023 – Based on preliminary, unaudited figures the German OTC pharmaceuticals company PharmaSGP has achieved revenues of between € 85.5 and € 86 million for financial year 2022. Thus, the Munich-based company reac [ … ]
Mon, 20.02.2023
PharmaSGP Holding SE
PharmaSGP achieves new record revenue of more than € 85.5 million for 2022 exceeding analysts’ expectations
Gräfelfing, 20 February 2023 – Based on preliminary, unaudited figures the German OTC pharmaceuticals company PharmaSGP has achieved revenues of between € 85.5 and € 86 million for financial year 2022. Thus, the Munich-based company reac [ … ]
Wed, 16.11.2022
PharmaSGP Holding SE
PharmaSGP posts record revenues (+39%) and record earnings (+54%) in 9M 2022 – raises full-year forecast
Gräfelfing, 16 November 2022 – German OTC pharmaceutical company PharmaSGP Holding SE has once again in the third quarter continued to experience the dynamic development seen in previous periods. Provisional unaudited figures show the compan [ … ]
Wed, 16.11.2022
PharmaSGP Holding SE
PharmaSGP posts record revenues (+39%) and record earnings (+54%) in 9M 2022 – raises full-year forecast
Gräfelfing, 16 November 2022 – German OTC pharmaceutical company PharmaSGP Holding SE has once again in the third quarter continued to experience the dynamic development seen in previous periods. Provisional unaudited figures show the compan [ … ]
Thu, 01.09.2022
PharmaSGP Holding SE
PharmaSGP reports record revenues (+59%) and record earnings (+86%) in the first half of 2022
Gräfelfing, 1 September 2022 – In the first half of 2022, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic performance of the previous quarters, achieving half-year revenues of € 42.0 million based on preliminary, unaudited [ … ]
Thu, 01.09.2022
PharmaSGP Holding SE
PharmaSGP reports record revenues (+59%) and record earnings (+86%) in the first half of 2022
Gräfelfing, 1 September 2022 – In the first half of 2022, German OTC pharmaceutical company PharmaSGP Holding SE continued its dynamic performance of the previous quarters, achieving half-year revenues of € 42.0 million based on preliminary, unaudited [ … ]
Thu, 21.07.2022
PharmaSGP Holding SE
PharmaSGP successfully secures financing of up to € 160 million
Gräfelfing, 21 July 2022 – Following strong organic growth and the successful acquisition and integration of the four OTC brands Baldriparan®, Formigran®, Spalt® and Kamol® formerly owned by the GlaxoSmithKline Group (GSK) in the second half of 2021, PharmaSGP Holding SE achieved r [ … ]